Pharmacokinetics and safety of gadobenate dimeglumine (Multihance) in subjects with impaired liver function

Investigative Radiology

Volumn 37, Issue 5, 2002, Pages 299-308

  Davies, Brian E ^a   Kirchin, Miles A ^a   Bensel, Kathleen ^a   Lorusso, Vito ^a   Davies, Alexandra ^a   Parker, John R ^a   Lafrance, Norman D ^a  

^a Bracco Imaging SpA   (Italy)

Author keywords

Contrast agents; Gadobenate dimeglumine; Gd BOPTA; Hepatic impairment; Liver MRI

Indexed keywords

GADOBENATE DIMEGLUMINE; PLACEBO;

ABDOMINAL PAIN; ADULT; AMBLYOPIA; AREA UNDER THE CURVE; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEMALE; HUMAN; INJECTION PAIN; KIDNEY CLEARANCE; LIVER DYSFUNCTION; MALE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINE LEVEL;

EID: 0036234522     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200205000-00008     Document Type: Article

References (38)

1. Contrast agents for MR imaging of the liver
2. Contrast agents for MR imaging of the liver
3. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers
4. Pharmacokinetic behavior of gadoteridol injection
5. Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers
6. A phase I clinical trial with Gd-DTPA-BMA injection, a non-ionic magnetic resonance imaging enhancement agent
7. Pharmacokinetics, safety and tolerability of gadoversetamide injection (Optimark) in subjects with central nervous system or liver pathology and varying degrees of renal function
8. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP
9. Gadobenate dimeglumine (GdBOPTA). An overview
10. MultiHance clinical pharmacology: Biodistribution and MR enhancement of the liver
11. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers
12. Transsection of the oesophageus for bleeding oesophageal varices
13. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment
14. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the MRI contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance)
15. Physiological parameters in laboratory animals and man
16. Bile-tagged 3D magnetic resonance colonography after exclusive intravenous administration of gadobenate dimeglumine, a contrast agent with partial hepatobiliary excretion
17. Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans
18. A toxicological risk for using manganese complexes? A literature survey of existing data through several medical specialities
19. Manganese intoxication and chronic liver failure
20. Cardiac metal contents after infusions of manganese: An experimental evaluation in the isolated rat heart
21. Spectroscopic and metabolic effects of MnCL2 and MnDPDP on the isolated and perfused rat heart
22. Neurotolerability of gadobenate dimeglumine. Evaluation of brain dopamine concentration in freely moving rats by microdialysis
23. Neurotolerability of contrast agents in rats with brain ischemia induced by transient middle cerebral artery occlusion: EEG evaluation
24. Comparative study between gadobenate dimeglumine and gadobutrol in rats with brain ischemia: Evaluation of somatosensory evoked potentials
25. Serum iron and serum bilirubin after administration of Gd-DTPA-dimeglumine: A pharmacologic study in healthy volunteers
26. Tolerance and safety of Gd-DTPA in 7000 patients: A review
27. Multicenter double blind placebo controlled study of gadopenetate dimeglumine as an MR contrast agent: Evaluation in patients with cerebral lesions
28. MR imaging of the liver with Resovist: Safety, efficacy, and pharmacodynamic properties
29. Safety assessment of gadobenate dimeglumine (Multihance): Extended clinical experience from phase I studies to post-marketing surveillance
30. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology
31. Gadobenate dimeglumine 0.5M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: Mechanistic studies in animals
32. Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat
33. Hepatic transport of gadobenate dimeglumine in TR-rats
34. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis
35. Hepatocellular Carcinoma: Correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings
36. Detection of intracranial metastases: A multi-center, intra-patient comparison of gadobenate-dimeglumine-enhanced MRI with routinely used contrast agents at equal dose